We're LIVE today at 7pm ET with myeloma specialist Dr. Douglas Sborov! Get ready to ask him all your myeloma questions as we close out #BloodCancerAwarenessMonth. Click "Going" on Facebook & turn on notifications to RSVP: https://www.facebook.com/events/1388778123259596/
#KnowMyeloma #mmsm
#KnowMyeloma #mmsm
September 29, 2026 at 2:53 PM
We're LIVE today at 7pm ET with myeloma specialist Dr. Douglas Sborov! Get ready to ask him all your myeloma questions as we close out #BloodCancerAwarenessMonth. Click "Going" on Facebook & turn on notifications to RSVP: https://www.facebook.com/events/1388778123259596/
#KnowMyeloma #mmsm
#KnowMyeloma #mmsm
📣 ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
September 29, 2026 at 8:52 AM
📣 ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
SESSION 6 "Hodgkin lymphoma"
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
In treating R/R #MMsm, BCMA-targeted CAR-T therapy prior to a bispecific antibody led to greater OS rates (79% vs. 63%) than did a bispecific antibody followed by CAR-T therapy, suggesting that such a sequencing strategy could improve survival probability: https://ow.ly/Q2X450ZRwY3
September 25, 2026 at 5:00 PM
In treating R/R #MMsm, BCMA-targeted CAR-T therapy prior to a bispecific antibody led to greater OS rates (79% vs. 63%) than did a bispecific antibody followed by CAR-T therapy, suggesting that such a sequencing strategy could improve survival probability: https://ow.ly/Q2X450ZRwY3
How can older myeloma patients decide what treatment is still worth pursuing? IMF NLB member Sam Shenoy answers and points to the IMF's free Decision-Making Tool at myeloma.org.
#AsktheIMF #KnowMyeloma #mmsm
#AsktheIMF #KnowMyeloma #mmsm
September 22, 2026 at 8:03 PM
How can older myeloma patients decide what treatment is still worth pursuing? IMF NLB member Sam Shenoy answers and points to the IMF's free Decision-Making Tool at myeloma.org.
#AsktheIMF #KnowMyeloma #mmsm
#AsktheIMF #KnowMyeloma #mmsm
The EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology
Read more: www.onclive.com/view/chmp-re...
Read more: www.onclive.com/view/chmp-re...
September 18, 2026 at 4:11 PM
The EMA's CHMP offered a positive opinion recommending the approval of teclistamab for the treatment of adult patients with R/R multiple myeloma who have received at least 1 prior therapy #mmsm #oncology
Read more: www.onclive.com/view/chmp-re...
Read more: www.onclive.com/view/chmp-re...
CHMP of the EMA issued a positive opinion supporting melflufen plus dexamethasone for the treatment of multiple myeloma after at least 2 prior lines of therapy that is refractory to lenalidomide and to the last line of therapy. #mmsm #oncology
www.onclive.com/view/chmp-re...
www.onclive.com/view/chmp-re...
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma | OncLive
CHMP offerred a positive opinion supporting extension of melflufen to third-line, lenalidomide-refractory multiple myeloma.
www.onclive.com
September 17, 2026 at 7:41 PM
CHMP of the EMA issued a positive opinion supporting melflufen plus dexamethasone for the treatment of multiple myeloma after at least 2 prior lines of therapy that is refractory to lenalidomide and to the last line of therapy. #mmsm #oncology
www.onclive.com/view/chmp-re...
www.onclive.com/view/chmp-re...
The latest version of the NCCN Guidelines for multiple myeloma include a dedicated section on MRD assessments with recommendations for clinical practice. Dive into the latest MRD updates and updated treatment recommendations #mmsm #oncology www.onclive.com/view/updated...
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma | OncLive
The latest updates to the NCCN Guidelines for multiple myeloma expand minimal residual disease testing guidance.
www.onclive.com
September 17, 2026 at 3:04 PM
The latest version of the NCCN Guidelines for multiple myeloma include a dedicated section on MRD assessments with recommendations for clinical practice. Dive into the latest MRD updates and updated treatment recommendations #mmsm #oncology www.onclive.com/view/updated...
It's #BloodCancerAwarenessMonth!
No one piece of evidence can uncover myeloma. Doctors look at abnormal blood tests, lab numbers, imaging scans, and other specialty tests to diagnose it. Tell us: How did you or your team figure out you had myeloma?
#KnowMyeloma #mmsm
No one piece of evidence can uncover myeloma. Doctors look at abnormal blood tests, lab numbers, imaging scans, and other specialty tests to diagnose it. Tell us: How did you or your team figure out you had myeloma?
#KnowMyeloma #mmsm
September 16, 2026 at 5:59 PM
It's #BloodCancerAwarenessMonth!
No one piece of evidence can uncover myeloma. Doctors look at abnormal blood tests, lab numbers, imaging scans, and other specialty tests to diagnose it. Tell us: How did you or your team figure out you had myeloma?
#KnowMyeloma #mmsm
No one piece of evidence can uncover myeloma. Doctors look at abnormal blood tests, lab numbers, imaging scans, and other specialty tests to diagnose it. Tell us: How did you or your team figure out you had myeloma?
#KnowMyeloma #mmsm
By 2034, 1 in 4 people diagnosed with myeloma will be African American. Knowing the early signs can be the key to timely diagnosis. Learn the symptoms to look for at knowmyeloma.org
#BloodCancerAwarenessMonth #mmsm #KnowMyeloma
#BloodCancerAwarenessMonth #mmsm #KnowMyeloma
September 15, 2026 at 4:59 PM
By 2034, 1 in 4 people diagnosed with myeloma will be African American. Knowing the early signs can be the key to timely diagnosis. Learn the symptoms to look for at knowmyeloma.org
#BloodCancerAwarenessMonth #mmsm #KnowMyeloma
#BloodCancerAwarenessMonth #mmsm #KnowMyeloma
📣 DISCOVER THE LEARNING OBJECTIVES OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
September 15, 2026 at 3:06 PM
📣 DISCOVER THE LEARNING OBJECTIVES OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
📣 PROGRAMME HIGHLIGHT OF #ESHLYMPHOMA2026
3 simultaneous Meet-the-Expert sessions
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #MMsm #Lmsm
3 simultaneous Meet-the-Expert sessions
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #MMsm #Lmsm
September 15, 2026 at 8:26 AM
📣 PROGRAMME HIGHLIGHT OF #ESHLYMPHOMA2026
3 simultaneous Meet-the-Expert sessions
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #MMsm #Lmsm
3 simultaneous Meet-the-Expert sessions
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #MMsm #Lmsm
#SeptemberReading 4) Miles Morales: Spider-man 41
Reprints MMSM 39 Thick as Thieves part 3 by Cody Ziglar, Luigi Zagaria & Bryan Valenza
Wrapping up the battle with Black Obsidian. Not sure if they cut something out but it’s only 18 pages, though one is a double page spread printed sideways
Reprints MMSM 39 Thick as Thieves part 3 by Cody Ziglar, Luigi Zagaria & Bryan Valenza
Wrapping up the battle with Black Obsidian. Not sure if they cut something out but it’s only 18 pages, though one is a double page spread printed sideways
September 13, 2026 at 9:23 AM
#SeptemberReading 4) Miles Morales: Spider-man 41
Reprints MMSM 39 Thick as Thieves part 3 by Cody Ziglar, Luigi Zagaria & Bryan Valenza
Wrapping up the battle with Black Obsidian. Not sure if they cut something out but it’s only 18 pages, though one is a double page spread printed sideways
Reprints MMSM 39 Thick as Thieves part 3 by Cody Ziglar, Luigi Zagaria & Bryan Valenza
Wrapping up the battle with Black Obsidian. Not sure if they cut something out but it’s only 18 pages, though one is a double page spread printed sideways
It’s an honor to be captain of Team @roswellpark.bsky.social and a Board of Trustee for @bloodcancerunited.bsky.social
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...
Matthew's Light The Night Fundraiser
About Light The Night At Blood Cancer United’s Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancer. Companies, community partners, friends, familie...
pages.lls.org
September 10, 2026 at 12:10 PM
It’s an honor to be captain of Team @roswellpark.bsky.social and a Board of Trustee for @bloodcancerunited.bsky.social
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...
2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology
September 9, 2026 at 8:17 PM
2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology
Just in 📰: The GPRC5D-directed CAR T-cell therapy arlo-cel met the primary ORR end point of the phase 2 QUINTESSENTIAL trial in patients with quadruple-class exposed, relapsed/refractory multiple myeloma #mmsm #oncology
Read more: www.onclive.com/view/arlo-ce...
Read more: www.onclive.com/view/arlo-ce...
September 8, 2026 at 2:22 PM
Just in 📰: The GPRC5D-directed CAR T-cell therapy arlo-cel met the primary ORR end point of the phase 2 QUINTESSENTIAL trial in patients with quadruple-class exposed, relapsed/refractory multiple myeloma #mmsm #oncology
Read more: www.onclive.com/view/arlo-ce...
Read more: www.onclive.com/view/arlo-ce...
I love an owner that would make me wear a ball gag often,, ,mmsm,, <3
September 8, 2026 at 7:58 AM
I love an owner that would make me wear a ball gag often,, ,mmsm,, <3
Key regulatory news in a pair of MPNs, plus data readouts in myeloma and lung cancer, highlight this week's top oncology news. Did you miss any of it? #mpnsm #mmsm #lcsm #oncology
Test your knowledge with this week's news quiz: www.onclive.com/view/onclive...
Test your knowledge with this week's news quiz: www.onclive.com/view/onclive...
OncLive Weekly News Quiz (9/4/2026): Did You Miss Key MPN, Myeloma, and Lung Cancer Updates? | OncLive
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
www.onclive.com
September 4, 2026 at 2:05 PM
Key regulatory news in a pair of MPNs, plus data readouts in myeloma and lung cancer, highlight this week's top oncology news. Did you miss any of it? #mpnsm #mmsm #lcsm #oncology
Test your knowledge with this week's news quiz: www.onclive.com/view/onclive...
Test your knowledge with this week's news quiz: www.onclive.com/view/onclive...
🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology
Dive into the efficacy/safety highlights: www.onclive.com/view/etentam...
Dive into the efficacy/safety highlights: www.onclive.com/view/etentam...
September 3, 2026 at 3:46 PM
🗞️Just in: Topline data from the phase 3 CERVINO trial showed etentamig generated statistically significant improvements in PFS and ORR vs standard therapies in patients with triple-class exposed R/R myeloma #mmsm #oncology
Dive into the efficacy/safety highlights: www.onclive.com/view/etentam...
Dive into the efficacy/safety highlights: www.onclive.com/view/etentam...
A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at @danafarber.bsky.social #mmsm #oncology www.onclive.com/view/giulian...
Giuliani Family Announces Remarkable Commitment of $27.8 Million to Dana-Farber Cancer Institute to Advance Progress in Multiple Myeloma Research | OncLive
A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at Dana-Farber Cancer Institute.
www.onclive.com
September 2, 2026 at 5:35 PM
A donation from Mario Germano Giuliani and Lisa Giuliani will support research in multiple myeloma at @danafarber.bsky.social #mmsm #oncology www.onclive.com/view/giulian...
Daraxonrasib wasn't the only notable @fda.gov #oncology approval in August. Revisit the key regulatory decisions from the month covering melanoma, multiple myeloma, gastric cancer, and polycythemia vera #melsm #mmsm #mpnsm
www.onclive.com/view/august-...
www.onclive.com/view/august-...
August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know | OncLive
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
www.onclive.com
September 2, 2026 at 3:01 PM
A huge congratulations to Dr. @vpizzuti.bsky.social and all our collaborators and my mentors at @accordsresearch.bsky.social, @cuanschutz.bsky.social / @cuhematology.bsky.social, and @uchicagomedicine.bsky.social. #lymsm #mmsm
September 1, 2026 at 2:20 AM
A huge congratulations to Dr. @vpizzuti.bsky.social and all our collaborators and my mentors at @accordsresearch.bsky.social, @cuanschutz.bsky.social / @cuhematology.bsky.social, and @uchicagomedicine.bsky.social. #lymsm #mmsm
Provocatively, we found that patients who later responded to CAR-T by D+90 had worse fatigue at D+15 vs nonresponders. By D+30, fatigue was similar.
Hypothesis-generating & suggests acute post-CAR-T patient-reported fatigue may be a novel “PRO-marker” of response. #lymsm #mmsm
Hypothesis-generating & suggests acute post-CAR-T patient-reported fatigue may be a novel “PRO-marker” of response. #lymsm #mmsm
September 1, 2026 at 2:20 AM
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social.
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bn...
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bn...
September 1, 2026 at 2:20 AM
Proud to share our @ash.hematology.org @bloodjournals.hematology.org, led by my trainee Dr. @vpizzuti.bsky.social @cuinternalmed.bsky.social.
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bn...
Longitudinal PROs and QoL trajectories over 2 years after CAR T-cell therapy. #lymsm #mmsm🧵
doi.org/10.1016/j.bn...